EA201892218A1 - Способы ингибирования ангиогенеза у пациента - Google Patents

Способы ингибирования ангиогенеза у пациента

Info

Publication number
EA201892218A1
EA201892218A1 EA201892218A EA201892218A EA201892218A1 EA 201892218 A1 EA201892218 A1 EA 201892218A1 EA 201892218 A EA201892218 A EA 201892218A EA 201892218 A EA201892218 A EA 201892218A EA 201892218 A1 EA201892218 A1 EA 201892218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
methods
angiogenesis
masp
inhibiting angiogenesis
Prior art date
Application number
EA201892218A
Other languages
English (en)
Inventor
Грегори А. Демопулос
Ханс-Вильхельм Швебле
Томас Дадлер
Ларри Хьелкер
Original Assignee
Омерос Корпорейшн
Юниверсити Оф Лестер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Омерос Корпорейшн, Юниверсити Оф Лестер filed Critical Омерос Корпорейшн
Publication of EA201892218A1 publication Critical patent/EA201892218A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В одном аспекте настоящее изобретение относится к способам предотвращения, лечения, возвращения к прежнему состоянию и/или замедления ангиогенеза у пациента, который является млекопитающим, страдающего от, или подверженного риску развития, зависимого от ангиогенеза заболевания или состояния, включающим введение пациенту количества ингибирующего MASP-2 средства, эффективного для ингибирования ангиогенеза. В некоторых вариантах осуществления этих аспектов изобретения ингибирующее MASP-2 средство представляет собой антитело против MASP-2 или его фрагмент.
EA201892218A 2016-03-31 2017-03-31 Способы ингибирования ангиогенеза у пациента EA201892218A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315857P 2016-03-31 2016-03-31
PCT/US2017/025411 WO2017173290A1 (en) 2016-03-31 2017-03-31 Methods for inhibiting angiogenesis in a subject in need thereof

Publications (1)

Publication Number Publication Date
EA201892218A1 true EA201892218A1 (ru) 2019-03-29

Family

ID=59959191

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892218A EA201892218A1 (ru) 2016-03-31 2017-03-31 Способы ингибирования ангиогенеза у пациента
EA202191185A EA202191185A1 (ru) 2016-03-31 2017-03-31 Способы ингибирования ангиогенеза у пациента

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202191185A EA202191185A1 (ru) 2016-03-31 2017-03-31 Способы ингибирования ангиогенеза у пациента

Country Status (19)

Country Link
US (2) US10870708B2 (ru)
EP (1) EP3436072A4 (ru)
JP (3) JP6865767B2 (ru)
KR (3) KR20180128941A (ru)
CN (3) CN115137816A (ru)
AU (2) AU2017240129B2 (ru)
BR (1) BR112018069732A2 (ru)
CA (2) CA3096270C (ru)
CL (1) CL2018002708A1 (ru)
EA (2) EA201892218A1 (ru)
GE (1) GEP20237466B (ru)
IL (2) IL305200A (ru)
MA (1) MA44518A (ru)
MX (2) MX2018011648A (ru)
MY (1) MY195432A (ru)
NZ (1) NZ745531A (ru)
PH (1) PH12018502046A1 (ru)
SG (2) SG11201808242UA (ru)
WO (1) WO2017173290A1 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US12029940B2 (en) 2019-03-11 2024-07-09 Rom Technologies, Inc. Single sensor wearable device for monitoring joint extension and flexion
US11904207B2 (en) 2019-05-10 2024-02-20 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains
US11957956B2 (en) 2019-05-10 2024-04-16 Rehab2Fit Technologies, Inc. System, method and apparatus for rehabilitation and exercise
US11433276B2 (en) 2019-05-10 2022-09-06 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength
US11957960B2 (en) 2019-05-10 2024-04-16 Rehab2Fit Technologies Inc. Method and system for using artificial intelligence to adjust pedal resistance
US12102878B2 (en) 2019-05-10 2024-10-01 Rehab2Fit Technologies, Inc. Method and system for using artificial intelligence to determine a user's progress during interval training
US11896540B2 (en) 2019-06-24 2024-02-13 Rehab2Fit Technologies, Inc. Method and system for implementing an exercise protocol for osteogenesis and/or muscular hypertrophy
US11071597B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Telemedicine for orthopedic treatment
US12062425B2 (en) 2019-10-03 2024-08-13 Rom Technologies, Inc. System and method for implementing a cardiac rehabilitation protocol by using artificial intelligence and standardized measurements
US11101028B2 (en) 2019-10-03 2021-08-24 Rom Technologies, Inc. Method and system using artificial intelligence to monitor user characteristics during a telemedicine session
US11915816B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states
US11955222B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria
US11069436B2 (en) 2019-10-03 2021-07-20 Rom Technologies, Inc. System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks
US11955220B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine
US11317975B2 (en) 2019-10-03 2022-05-03 Rom Technologies, Inc. Method and system for treating patients via telemedicine using sensor data from rehabilitation or exercise equipment
US11887717B2 (en) 2019-10-03 2024-01-30 Rom Technologies, Inc. System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine
US11075000B2 (en) 2019-10-03 2021-07-27 Rom Technologies, Inc. Method and system for using virtual avatars associated with medical professionals during exercise sessions
US11923065B2 (en) 2019-10-03 2024-03-05 Rom Technologies, Inc. Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine
US11961603B2 (en) 2019-10-03 2024-04-16 Rom Technologies, Inc. System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine
US12020800B2 (en) 2019-10-03 2024-06-25 Rom Technologies, Inc. System and method for using AI/ML and telemedicine to integrate rehabilitation for a plurality of comorbid conditions
US11978559B2 (en) 2019-10-03 2024-05-07 Rom Technologies, Inc. Systems and methods for remotely-enabled identification of a user infection
US11955223B2 (en) 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions
US11955221B2 (en) * 2019-10-03 2024-04-09 Rom Technologies, Inc. System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis
US11915815B2 (en) 2019-10-03 2024-02-27 Rom Technologies, Inc. System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated
US12020799B2 (en) 2019-10-03 2024-06-25 Rom Technologies, Inc. Rowing machines, systems including rowing machines, and methods for using rowing machines to perform treatment plans for rehabilitation
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CA3159176A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
CA3159167A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
US11107591B1 (en) 2020-04-23 2021-08-31 Rom Technologies, Inc. Method and system for describing and recommending optimal treatment plans in adaptive telemedical or other contexts
US12100499B2 (en) 2020-08-06 2024-09-24 Rom Technologies, Inc. Method and system for using artificial intelligence and machine learning to create optimal treatment plans based on monetary value amount generated and/or patient outcome
KR20220031412A (ko) 2020-09-04 2022-03-11 주식회사 엘지에너지솔루션 배터리 관리 장치 및 방법
CA3240483A1 (en) 2021-12-10 2023-06-15 Thomas Dudler Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US20240228499A1 (en) 2022-11-30 2024-07-11 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
PT2374819T (pt) 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20130266559A1 (en) * 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US11130801B2 (en) * 2011-01-13 2021-09-28 Case Western Reserve University Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
CA3076975C (en) 2011-04-08 2024-06-18 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
CA3131223C (en) * 2011-05-04 2024-01-30 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
AU2012272706B2 (en) * 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
EP3058951A1 (en) 2012-06-18 2016-08-24 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
SI3057993T1 (sl) * 2013-10-17 2021-03-31 Omeros Corporation Postopki za zdravljenje bolezenskih stanj, povezanih z aktivacijo komplementov, odvisnih od MASP-2
JP6369862B2 (ja) 2014-08-06 2018-08-08 原　英彰 眼内血管新生抑制剤及びその用途

Also Published As

Publication number Publication date
CA3096270A1 (en) 2017-10-05
CA3018774C (en) 2023-02-28
CA3018774A1 (en) 2017-10-05
JP2022110159A (ja) 2022-07-28
MA44518A (fr) 2019-02-06
US20210189009A1 (en) 2021-06-24
EP3436072A1 (en) 2019-02-06
AU2017240129A1 (en) 2018-09-06
EA202191185A1 (ru) 2021-10-29
JP2020125332A (ja) 2020-08-20
MX2022012380A (es) 2022-10-31
US11981748B2 (en) 2024-05-14
JP2019513715A (ja) 2019-05-30
CN117582494A (zh) 2024-02-23
IL305200A (en) 2023-10-01
AU2020201633B2 (en) 2022-03-31
CL2018002708A1 (es) 2019-01-11
JP6865767B2 (ja) 2021-04-28
CN115137816A (zh) 2022-10-04
US20170283508A1 (en) 2017-10-05
SG10202009886SA (en) 2020-11-27
KR20230019991A (ko) 2023-02-09
AU2017240129B2 (en) 2020-04-02
GEP20237466B (en) 2023-01-25
CA3096270C (en) 2024-05-21
EP3436072A4 (en) 2019-11-06
BR112018069732A2 (pt) 2019-02-05
KR20200113290A (ko) 2020-10-06
NZ745531A (en) 2020-09-25
SG11201808242UA (en) 2018-10-30
CN109152834A (zh) 2019-01-04
IL262021A (en) 2018-10-31
MY195432A (en) 2023-01-20
AU2020201633A1 (en) 2020-03-19
IL262021B1 (en) 2023-09-01
MX2018011648A (es) 2019-01-30
PH12018502046A1 (en) 2019-07-08
IL262021B2 (en) 2024-01-01
KR20180128941A (ko) 2018-12-04
US10870708B2 (en) 2020-12-22
WO2017173290A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
EA201892218A1 (ru) Способы ингибирования ангиогенеза у пациента
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112017008093A2 (pt) processos para tratamento de doenças oculares
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
EA201500364A1 (ru) Лечение глазных заболеваний
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
EA202190106A1 (ru) Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA201891968A1 (ru) Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
BR112022003884A2 (pt) Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii
EA201692155A1 (ru) МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
UY38506A (es) Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotrofica
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA201990559A1 (ru) Комбинированная терапия
EA201992522A1 (ru) КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
MX2020013306A (es) Uso de compuestos de halogeno para el tratamiento y prevencion de lesiones tisulares y sindrome post-cuidados intensivos.